A Clinical Study to Evaluate the Effect of HDP-101 for the Treatment of Multiple Myeloma

Trial Profile

A Clinical Study to Evaluate the Effect of HDP-101 for the Treatment of Multiple Myeloma

Planning
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs HDP 101 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2018 According to a Heidelberg Pharma AG media release, preparations for initiation of this trial are underway and several highly renowned centers have been enlisted for this trial with Heidelberg Pharma acting as a trial design advisor.
    • 11 Oct 2018 According to a Heidelberg Pharma AG media release, the company has brought several important and renowned clinical centers in Germany, Spain and the USA on board for HDP-101 project and will continue to push ahead with trial planning together with these institutions.The company is planning to submit the trial application in the second quarter of 2019 and depending on how the approval procedure unfolds, the first patients could start receiving treatment in the second half of 2019.
    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top